QUINCE THERAPEUTICS INC (QNCX) Stock News

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Quince Therapeutics (NASDAQ:QNCX) just reported results for the second quarter ...

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024

Quince Therapeutics just reported results for the second quarter of 2024.

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024

Quince Therapeutics just reported results for the first quarter of 2024.

This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Mentions: DV BOX LNTH KALV

Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023

Quince Therapeutics just reported results for the fourth quarter of 2023.

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

This Edison International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Mentions: DLTR EIX MLM VMC ...

Quince Therapeutics to Participate at Upcoming Investor Conferences

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System

Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results

Quince Therapeutics Launches Scientific Advisory Board

Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors

Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

Quince Therapeutics to Participate at Investor Events in January 2024

Quince Therapeutics Completes Acquisition of EryDel S.p.A.

FDA lifts partial clinical hold on EryDel lead product EryDex (QNCX)

Quince Therapeutics said the FDA has lifted a partial clinical hold on the lead product of its merger partner, EryDel. Phase 3 testing is expected to begin after the deal closes.